Ascendis Pharma

#PRESS New research published in Expert Review of Clinical Pharmacology describes the important role of endogenous parathyroid hormone (PTH) in the highly regulated synthesis of active Vitamin D, and its disruption in #hypoparathyroidism (DOI: 10.1080/17512433.2026.2718374).

#PRESS #AscendisPharma is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of our treatment for children with #achondroplasia two years of age and older whose epiphyses are not closed. The European Commission will consider the CHMP recommendation, with a final decision expected by the end of this year. Learn more: https://lnkd.in/gF4_7gm8

As this year’s Meeting of the European Society for Paediatric Endocrinology #ESPE2026 comes to a close, we are grateful to the endocrinology community for taking the time to reflect on the future of #achondroplasia care and share their hopes and aspirations. The aspirations shared at #ESPE2026 highlighted a collective ambition to improve quality of life outcomes and better support children and families affected by #achondroplasia. We look forward to building on these conversations and continuing the dialogue beyond ESPE.

#AscendisPharma is proud to be funding “Closing the Policy Gap in Rare Diseases: The Case of Hypoparathyroidism,” an event hosted by Pascal Arimont at the European Parliament in Brussels. #Hypoparathyroidism is a rare endocrine disease that is linked to multi-organ manifestations and can cause a wide range of symptoms and complications. This hybrid event brings patients, advocates, clinical experts, and policymakers together to discuss the unmet needs of people living with hypoparathyroidism and explore EU policy pathways around #RareDiseases, #WomensHealth, #BrainHealth and #HealthEquity. 📅 September 30 | 13:30–15:30 CEST 📍 European Parliament, Brussels (in-person and online) 👉 Learn more and register: https://lnkd.in/eUAdQRVY

Thank you to everyone who visited the Ascendis Pharma booth during the 64th Annual Meeting of the European Society for Paediatric Endocrinology #ESPE2026. We were delighted to connect with the endocrinology community for conversations centered on the impact of #achondroplasia on bone and beyond, and the importance of seeing the condition through the eyes of those living with it every day. By stepping into a space designed around children with #achondroplasia, attendees were invited to hear directly from children and families and experience a more personal perspective on the realities of living with the condition. What was your highlight from this year’s meeting?

Today is #WorldPatientSafetyDay and we are proud to spotlight Dr. Jethro Ekuta, Chief Regulatory & Safety Officer, who shares how patient safety drives our mission every day. At #AscendisPharma, each member of our team works to help support compliance with global health regulations. #PatientSafety